phase II

Phase 2Protein / enzyme

KKK Women's and Children's Hospital

phase II is one of 89 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Patients With Solid TumorsNot yet recruiting

Advanced Solid TumorsPhase 2

Recruiting

Patients With Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

51 2

Opdivo

Bristol-Myers Squibb

Phase 2

19 3

Fludara

Sanofi

Phase 2

16 4

Avastin

Roche

Phase 2

15 5

Tecentriq

Roche

Phase 2

11 6

Abraxane

Bristol-Myers Squibb

Phase 2

11 7

Yervoy

Bristol-Myers Squibb

Phase 2

6 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 9

Lenvima

Eisai

Phase 2

5 10

Erbitux

IImclone

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06464055

Q4 2029

Phase 1/2Not yet recruiting

Patients With Solid Tumors

NCT07446725

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting·GGeneQuantum Healthcare (Suzhou) Co., Ltd.·Phase 1/2·NCT06464055·260 enrolled

Patients With Solid Tumors1 trial

A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors

Not yet recruiting·SSuzhou Genhouse Bio Co., Ltd.·Phase 1/2·NCT07446725·152 enrolled

Refractory1 trial

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Unknown status·KKK Women's and Children's Hospital·Phase 1/2·NCT05429905·48 enrolled

Peripheral T-cell Lymphomas (PTCL)1 trial

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Completed·FFondazione Italiana Linfomi - ETS·Preclinical·NCT02223208·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for phase II. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — phase II compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for phase II. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — KK Women's and Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: KKK Women's and Children's Hospital

phase II

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Patients With Solid Tumors1 trial

Refractory1 trial

Peripheral T-cell Lymphomas (PTCL)1 trial

References

Drug Info

Quick Facts

Related News